Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Cancer/Tumors Clinical Trials

A listing of Cancer/Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (564) clinical trials

Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma

Glioblastomas (GBMs) are the most common malignant primary brain tumors. Despite multimodality aggressive therapies (surgery followed by chemoradiotherapy based on TMZ and adjuvant TMZ), median overall survival is only 12 to 15 months. This dramatic behavior is mainly due to the high invasiveness and proliferation rate of GBM. In addition, ...

Phase

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Mismatch repair genes normally serve to fix the small glitches that occur when DNA is copied as cells divide. In 1993, researchers discovered that mutations in human mismatch repair genes play a key role in the development of certain forms of colorectal cancer; individuals who are deficient in these mismatch ...

Phase

Rigosertib for RDEB-SCC

Epidermolysis bullosa (EB) is a heritable skin disease characterized by marked fragility of epithelialized tissue with blistering in skin and mucous membranes following the slightest mechanical trauma. Eighty percent of all patients suffering from recessive dystrophic EB (RDEB), a subtype originating from mutations in the COL7A1 gene, develop squamous cell ...

Phase

A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)

PARC is an international phase I/II trial evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) in children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade gliomas (brain cancers). Currently the outcomes for these patients are poor and the therapeutic options are limited with a ...

Phase

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts: EXP-1: ROS1 TKI-nave ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy is allowed EXP-2: 1 Prior ROS1 TKI ROS1+ NSCLC. Disease progression, unresponsive, or intolerant to one prior line of a ROS1 TKI. ...

Phase

[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma

There is great need for new therapeutic options for patients with hepatocellular carcinoma (HCC). This proposal will assess the feasibility of a novel theranostic approach to HCC using [68Ga]DOTATATE, a recently approved positron emission tomography (PET) ligand for imaging somatostatin receptor (SSTR) positive tumors. In this study, we will use ...

Phase

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Background We generated a chimeric antigen receptor (CAR) that engages CD70 using its natural ligand CD27, as the binding moiety. Transducing peripheral blood lymphocytes (PBL) with this CAR conveys major histocompatibility complex (MHC)-independent recognition of CD70-expressing target cells, which include renal cell carcinoma and other cancers. In co-cultures with CD70+ ...

Phase

Avelumab Utomilumab Anti-OX40 Antibody PF-04518600 and Radiation Therapy in Treating Patients With Advanced Malignancies

PRIMARY OBJECTIVES: I. For Arms D-F, to establish the safety, tolerability, and dose-limiting toxicities (DLTs) of different treatment combinations of avelumab when administered in combination with checkpoint agonist(s) with or without radiation in patients with metastatic solid tumors in order to estimate the maximum tolerated dose (MTD) and select the ...

Phase

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK ROS1 OR NTRK1-3 Alterations

Enrollment of subjects into Phase 1 will proceed concurrently by age as follows: Subjects 4 to <12 years old will initially be enrolled in the Phase 1 part to determine the pediatric RP2D for this age group. Phase 1: Approximately 12 pediatric subjects with locally advanced or metastatic solid tumors, ...

Phase

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

Background Although malignant gliomas display genetic heterogeneity, several key proliferation and survival signaling pathways have been identified. Recent work has focused on targeting these tumor specific pathways in hopes of improving treatment efficacy and minimizing treatment toxicity. Because molecularly targeted agents have been mostly ineffective when used alone, combination therapy ...

Phase